On September 9, 2022, during the 2nd China Pharmaceutical Distribution and Trade Conference and the 2nd World Pharmaceutical Retail Conference, the Xingchen Capital Forum, sponsored by Hongjitang, was successfully held.

The Xingchen Capital Forum was attended by a distinguished group of leaders and experts, including:

• Liu Zhongliang, Executive Vice President and Secretary General of the China Pharmaceutical Materials Association
• Liu Jingrong, Executive Vice President and Vice President of Dazhenglin Pharmaceutical Group
• Wang Jinxia, Senior Advisor of the Association
• Huang Zhi, Chairman of Xinggong Co., Ltd.
• Zhang Zhefeng, Chairman of Chihealbop
• Yu Jing, Partner of Mifang Health Fund
• Shen Peiqiang, Senior Partner / Deputy Director of Accounting / Deputy General Manager of Tianjian
• Zhong Desong, General Manager of the Investment Banking Division at Minsheng Securities
• Song Wei, Executive General Manager of the Medical and Healthcare Division at Guojin Securities
• Wang Yunjun, Founder of Zhigu ESOP and former Partner at Deloitte
• Li Li, Partner in Life Sciences and Healthcare at Ernst & Young China
• Zhang Meng, First-Grade Equity Partner at Tongshang Law Firm
• Liu Hongbo, Managing Director at Haier Capital

These financial industry experts, representatives of listed companies and pre-listed enterprises, gathered at the forum to discuss and share insights.

       In his speech, Liu Zhongliang emphasized that the China Pharmaceutical Materials Association attaches great importance to the development of the Listing Development Committee platform. With clear strategic goals, the association aims to nurture 100 listed companies within the next 5-10 years. The Capital Forum was organized to align with the association’s objectives, bringing together various stakeholders, including brokerages, accounting firms, law firms, and financial capital. The goal is to attract more third-party service providers and potential, incubable pharmaceutical industrial enterprises. By collaborating, they aim to expand and strengthen this platform, which represents the mission and responsibility of the China Pharmaceutical Materials Association.

Zhang Zhefeng, Chairman of Chihealbio delivered a keynote speech titled "New Capital Opportunities in the Pharmaceutical Industry Under the New Policies". He analyzed the current policy landscape and inspired insights into the future development prospects for enterprises. Zhang expressed confidence that with the support of diverse capital investments, the collaboration between the healthcare industry and capital will yield fruitful outcomes, achieving mutual empowerment and fostering win-win success.